Show simple item record

dc.contributor.authorLopez, JA
dc.contributor.authorCrosbie, G
dc.contributor.authorKelly, C
dc.contributor.authorMcGee, AM
dc.contributor.authorWilliams, K
dc.contributor.authorVuckovic, S
dc.contributor.authorSchuyler, R
dc.contributor.authorRodwell, R
dc.contributor.authorWright, SJ
dc.contributor.authorTaylor, K
dc.contributor.authorHart, DNJ
dc.date.accessioned2011-05-10
dc.date.accessioned2014-05-15T22:29:35Z
dc.date.accessioned2017-03-01T23:51:35Z
dc.date.available2017-03-01T23:51:35Z
dc.date.issued2002
dc.date.modified2014-05-15T22:29:35Z
dc.identifier.issn0022-1759
dc.identifier.doi10.1016/S0022-1759(02)00185-0
dc.identifier.urihttp://hdl.handle.net/10072/59162
dc.description.abstractThe fundamental role of dendritic cells (DC) in initiating and directing the primary immune response is well established. Furthermore, it is now accepted that DC may be useful in new vaccination strategies for preventing certain malignant and infectious diseases. As blood DC (BDC) physiology differs from that of the DC homologues generated in vitro from monocyte precursors, it is becoming more relevant to consider BDC for therapeutic interventions. Until recently, protocols for the isolation of BDC were laborious and inefficient; therefore, their use for investigative cancer immunotherapy is not widespread. In this study, we carefully documented BDC counts, yields and subsets during apheresis (Cobe Spectra), the initial and essential procedure in creating a BDC isolation platform for cancer immunotherapy. We established that an automated software package (Version 6.0 AutoPBPC) provides an operator-independent reliable source of mononuclear cells (MNC) for BDC preparation. Further, we observed that BDC might be recovered in high yields, often greater than 100% relative to the number of circulating BDC predicted by blood volume. An average of 66 million (range, 17–179) BDC per 10-l procedure were obtained, largely satisfying the needs for immunization. Higher yields were possible on total processed blood volumes of 15 l. BDC were not activated by the isolation procedure and, more importantly, both BDC subsets (CD11c+CD123low and CD11cCD123high) were equally represented. Finally, we established that the apheresis product could be used for antibody-based BDC immunoselection and demonstrated that fully functional BDC can be obtained by this procedure.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.languageEnglish
dc.publisherNorth-Holland Publishing Company
dc.publisher.placeNetherlands
dc.relation.ispartofpagefrom199
dc.relation.ispartofpageto212
dc.relation.ispartofissue2
dc.relation.ispartofjournalJournal Immunological Methods
dc.relation.ispartofvolume267
dc.subject.fieldofresearchTumour Immunology
dc.subject.fieldofresearchImmunology
dc.subject.fieldofresearchOpthalmology and Optometry
dc.subject.fieldofresearchcode110709
dc.subject.fieldofresearchcode1107
dc.subject.fieldofresearchcode1113
dc.titleMonitoring and isolation of blood dendritic cells from apheresis products in healthy individuals: A platform for cancer immunotherapy
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codec1x
gro.facultyFaculty of Science, Environment, Engineering and Technology
gro.date.issued2002
gro.hasfulltextNo Full Text
gro.griffith.authorLopez Ramirez, Alejandro


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record